Final Analysis of the Phase 1b Chemotherapy And Venetoclax in Elderly Acute Myeloid Leukaemia Trial (CAVEAT)
- Author(s)
- Chua, CC; Loo, S; Fong, CY; Ting, SB; Tiong, IS; Fleming, SA; Anstee, NS; Ivey, A; Ashby, M; Teh, TC; Reynolds, J; Roberts, AW; Wei, AH;
- Journal Title
- Blood Advances
- Publication Type
- Online publication before print
- Abstract
- Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.8 months. The CAVEAT induction combined cytarabine and idarubicin with 5 dose levels of venetoclax (50-600 mg) for up to 14 days. Two additional cohorts explored adjusted-dose venetoclax (50 mg, 100 mg) with posaconazole. CAVEAT induction was well tolerated, with low mortality (4%) and limited high-grade gastrointestinal toxicity (4%). Delayed hematological recovery after consolidation was ameliorated by omitting idarubicin from post-remission therapy. The overall response rate (ORR: CR + CRh + CRi) was 75% with a median overall survival (OS) of 19.3 months (95% CI 11.1-31.3). Among de novo AML, ORR was 88% and median OS 33.1 months (95% CI 19.3-54.3). Almost one-third have not relapsed, many benefiting from prolonged treatment-free remission (median 17.9 months). CAVEAT induction was well tolerated and associated with high ORR that was durable, particularly for de novo AML. CAVEAT represents an effective time-limited treatment option for fit older patients with AML. (https://www.anzctr.org.au; ACTRN12616000445471).
- Department(s)
- Pathology
- Publisher's Version
- https://doi.org/10.1182/bloodadvances.2024014900
- Open Access at Publisher's Site
https://doi.org/10.1182/bloodadvances.2024014900- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-01-28 02:47:05
Last Modified: 2025-01-28 02:54:38